ARS Pharmaceuticals (SPRY) announced the Opposition Division of the European Patent Office, the EPO, upheld the validity of all claims in EP 3678649, which is a patent validated in over 30 European countries directed to nasal spray epinephrine formulations including alkyl-glycoside, such as Intravail, and uses thereof. ARS Pharma’s issued global intellectual property portfolio related to neffy provides coverage until at least 2039.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY:
- ARS Pharmaceuticals: Strategic Financial Maneuvers and Market Potential Drive Buy Rating
- ARS Pharmaceuticals Secures $250 Million Credit Agreement
- ARS Pharmaceuticals Gains Momentum: Buy Rating Justified by Market Share and Script Volume Increase
- Raymond James positive on ARS Pharmaceuticals after weekly data
- 3 Best Stocks to Buy Now, 9/23/2025, According to Top Analysts